The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, prospective observational study of chemotherapy in elderly patients with biliary tract cancer.
 
Kohei Nakachi
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; MSD; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zymeworks
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kouji Yamamoto
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yuta Maruki
No Relationships to Disclose
 
Kenji Ikezawa
Speakers' Bureau - Asahi Kasei; AstraZeneca; Chugai Pharma; Guardant Health; Incyte; MSD; Myriad Genetics; Nihon Servier; Taiho Pharmaceutical; Yakult Honsha
 
Takeshi Terashima
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Satoshi Shimizu
Research Funding - AstraZeneca (Inst); IQvia (Inst); Nihon Servier (Inst)
 
Kotoe Oshima
No Relationships to Disclose
 
Kunihiro Tsuji
No Relationships to Disclose
 
Hiroshi Nakase
No Relationships to Disclose
 
Hidetaka Tsumura
No Relationships to Disclose
 
Taro Shibuki
No Relationships to Disclose
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Naohiro Okano
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yukiyasu Okamura
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Novartis Pharmaceuticals UK Ltd.; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Tatsunori Sato
No Relationships to Disclose
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; J-Pharma; MSD; Novartis; Ohara Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; J-Pharma; MSD; OncoTherapy Science
 
Hiroaki Nagano
No Relationships to Disclose